iBio, Inc.

IBIO Nasdaq CIK: 0001420720

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 600 MADISON AVENUE, SUITE 1601, NEW YORK, NY, 10022-1737
Mailing Address 600 MADISON AVENUE, SUITE 1601, NEW YORK, NY, 10022-1737
Phone 302 355-0650
Fiscal Year End 0630
EIN 262797813

Financial Overview

FY2025

$28.73M
Total Assets

Recent SEC Filings

Form Type Date Filed Document
10-Q Quarterly financial report February 10, 2026 View on SEC
8-K Current report of material events February 10, 2026 View on SEC
4 Insider stock transaction report January 30, 2026 View on SEC
4 Insider stock transaction report January 30, 2026 View on SEC
S-3 Shelf registration for future offerings January 30, 2026 View on SEC
4 Insider stock transaction report January 30, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment January 29, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) January 22, 2026 View on SEC
8-K Current report of material events January 12, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) December 19, 2025 View on SEC

Annual Reports

10-K September 5, 2025
  • Advanced lung fibrosis drug to mid-stage trials
  • Launched IBIO-600 and IBIO-610 programs
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.